• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Animal & Veterinary

  • Print
  • Share
  • E-mail

ANADA 200-141 Isoflurane, USP - original approval

Approval Date: July 26, 1994

I. GENERAL INFORMATION:

NADA200-141
Sponsor:Inhalon Pharmaceuticals, Inc.
P.O. Box 21170
Lehigh Valley, PA 18002-1170
Generic Name:isoflurane, USP
Trade Name:Isoflurane, USP
Marketing Status:Prescription

 

II. INDICATIONS FOR USE

Isoflurane, USP is used for induction and maintenance of general anesthesia in horses and dogs.

 

III. DOSAGE

A.DOSAGE FORMIsoflurane, USP is a clear, colorless, stable liquid containing no additives or chemical stabilizers
B.ROUTE OF ADMINISTRATIONInhalation.
C.RECOMMENDED DOSAGES: 
 HorsesFor induction of anesthesia: Inspired concentrations of 3.0 to 5.0% isoflurane with oxygen, following a barbiturate anesthetic induction, are used to induce surgical anesthesia in the horse.
For maintenance of anesthesia: Inspired concentrations of 2.0 to 2.5% isoflurane with oxygen, following a barbiturate anesthetic induction, are used to induce surgical anesthesia in the dog.
 DogsFor induction of anesthesia: Inspired concentrations of 2.0 to 2.5% isoflurane with oxygen, following a barbiturate anesthetic induction, are used to induce surgical anesthesia in the dog.
For maintenance of anesthesia: Surgical levels of anesthesia may be sustained using a 1.5 to 1.8% concentration of isoflurane in oxygen.

 

IV. & V. EFFECTIVENESS AND ANIMAL TARGET

Under the provisions of the Federal Food, Drug, and Cosmetic Act, as amended by the Generic Animal Drug and Patent Term Restoration Act (53 FR 50460, December 15, 1988; first GADPTRA Policy Letter), an Abbreviated New Animal Drug Application (ANADA) may be submitted for a generic version of an approved new animal drug (pioneer product). For certain dosage forms, the Agency grants a waiver from conducting an in vivo bioequivalence study (55 FR 24645, June 18, 1990; fifth GADPTRA Policy Letter). In lieu of bioequivalence testing, the safety and efficacy of the generic product are based on the demonstrated chemical equivalence to the pioneer product.

Based on the formulation characteristics of the generic product, Inhalon Pharmaceuticals, Inc. was granted a waiver on April 4, 1994 (photocopy attached) from conducting an in vivo bioequivalence study with Isoflurane, USP. The generic and pioneer products are liquid anesthetics with the same inactive ingredients and the same concentrations of the active ingredient.

 

VI. HUMAN SAFETY:

Human Safety Relative to Food Consumption: Regarding consumption of drug residues in food, human safety data were not required for approval of this ANADA. This drug is for use in dogs, which are non-food animals, and for horses that are not to be used for food, and is labeled: "Warning: Not for use in horses intended for food."

Human Safety Relative to Possession, Handling and Administration: A cautionary statement which pertains to the safety of this drug product for humans is included in the labeling of the drug product, as follows: "Caution: Operating rooms should be provided with adequate ventilation to prevent the accumulation of anesthetic vapors."

 

VII AGENCY CONCLUSIONS:

This is an Abbreviated New Animal Drug Application (ANADA) filed under Section 512(b)(2) of the Federal, Food, Drug and Cosmetic (FFD& C) Act.

Safety and effectiveness for this generic animal drug, Isoflurane, USP, were established by demonstration of chemical equivalence to the pioneer product, Anaquest, Inc.'s AErrane ® (Isoflurane, USP, NADA 135-773).

This generic product and the pioneer product have identical labeling indications for use. The route and method of administration of the two drugs are identical. Both drugs are administered by inhalation. The generic and pioneer products are both liquid anesthetics that contain the same active and inactive ingredients in the same concentrations. Therefore, in compliance with FDA policy promulgated to implement Section 512(b)(2) of the FFD& C Act, no additional safety, efficacy, or in vivo bioequivalency studies were necessary or required.

This ANADA satisfies the requirements of section 512 of the Act and demonstrates that Isoflurane, USP is safe and effective for its labeled indications when used under its proposed conditions of use.

 

VIII. LABELING (Attached)

Copies of applicable labels may be obtained by writing to the:

Food and Drug Administration
Freedom of Information Staff (HFI-35)
5600 Fishers Lane
Rockville, MD 20857

Or requests may be sent via fax to: (301) 443-1726. If there are problems sending a fax, call (301) 443-2414.